Crescendo Biologics Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Jan 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for IL-17A binding proteins (US 11,667,705) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 2 fees due Mar 3 to 5, 2027 · next Mar 3
- 1 fee due May 14, 2027The maintenance fee for Single Domain Antibodies to Programmed Cell Death (PD-1) (US 11,814,429) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Chimeric Antigen Receptor with Single Domain Antibody (US 11,866,510) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Therapeutic Molecules That Bind to LAG3 and PD1 (US 11,951,172) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
- 1 fee due Nov 19, 2027The maintenance fee for IL-17A binding proteins (US 10,654,924) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,547,099 | Transgenic Mice In force · High confidence | In force | High confidence | |
| US 10,654,924 | IL-17A binding proteins In force · USPTO record | In force | USPTO record | |
| US 10,400,030 | Methods for Producing Optimised Therapeutic Molecules In force · High confidence | In force | High confidence | |
| US 11,746,158 | Therapeutic Molecules In force · High confidence | In force | High confidence | |
| US 11,667,705 | IL-17A binding proteins In force · USPTO record | In force | USPTO record | |
| US 11,866,510 | Chimeric Antigen Receptor with Single Domain Antibody In force · High confidence | In force | High confidence | |
| US 10,975,161 | Molecules that Bind Prostate Specific Membrane Antigen (PSMA) In force · High confidence | In force | High confidence | |
| US 10,947,308 | Composition for treatment of disorders In force · USPTO record | In force | USPTO record | |
| US 11,591,398 | Single Domain Antibodies to Programmed Cell Death Protein 1 (PD-1) In force · High confidence | In force | High confidence | |
| US 11,814,429 | Single Domain Antibodies to Programmed Cell Death (PD-1) In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 13: 8 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 13 no status recorded